64Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors

Mirzaei, Siroos; Revheim, Mona-Eilsabeth; Raynor, William; Zehetner, Walter; Kabos, Peter; Zandieh, Shahin; Alavi, Abass

doi:10.1007/s40487-019-00104-1

Cited by 14 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recent clinical studies, particularly head-to-head comparisons of [ 64 Cu]Cu-DOTA-TATE with both [ 111 In]In-DOTA-TATE [36] and [ 68 Ga]Ga-DOTA-TOC [37] revealed an overall better performance of the 64 Cu-conjugated in terms of sensitivity, resolution and rate of lesion detection. Additionally, other first-in-human studies with [ 64 Cu]Cu-DOTA-TOC also showed high lesion detection rate, safety of use and high effectiveness for predicting treatment planning [38]. Even more recently, Loft et.al.…”

Section: Introductionmentioning

confidence: 95%

Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets

et al. 2022

View full text Add to dashboard Cite

PET imaging has gained significant momentum in the last few years, especially in the area of oncology, with an increasing focus on metal radioisotopes owing to their versatile chemistry and favourable physical properties. Copper-61 (t1/2 = 3.33 h, 61% β+, Emax = 1.216 MeV) provides unique advantages versus the current clinical standard (i.e., gallium-68) even though, until now, no clinical amounts of 61Cu-based radiopharmaceuticals, other than thiosemicarbazone-based molecules, have been produced. This study aimed to establish a routine production, using a standard medical cyclotron, for a series of widely used somatostatin analogues, currently labelled with gallium-68, that could benefit from the improved characteristics of copper-61. We describe two possible routes to produce the radiopharmaceutical precursor, either from natural zinc or enriched zinc-64 liquid targets and further synthesis of [61Cu]Cu-DOTA-NOC, [61Cu]Cu-DOTA-TOC and [61Cu]Cu-DOTA-TATE with a fully automated GMP-compliant process. The production from enriched targets leads to twice the amount of activity (3.28 ± 0.41 GBq vs. 1.84 ± 0.24 GBq at EOB) and higher radionuclidic purity (99.97% vs. 98.49% at EOB). Our results demonstrate, for the first time, that clinical doses of 61Cu-based radiopharmaceuticals can easily be obtained in centres with a typical biomedical cyclotron optimised to produce 18F-based radiopharmaceuticals.

show abstract

Section: Introductionmentioning

confidence: 95%

Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Tables 1 and 2 show examples of medical uses and decay information for some of these pairs. For example, copper-64 ( 64 Cu) labeled DOTATATE ([ 64 Cu]Cu-DOTATATE) and [ 177 Lu]Lu-DOTATATE for NETs 37 . Different elements used to label a pharmaceutical are not guaranteed to have identical in vivo biological behavior in the body, but it is often assumed they do for treatment planning and dosimetry.…”

Section: Classes Of Theranostic Pairsmentioning

confidence: 99%

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs

Miller¹,

Rousseau²,

Ramogida³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Theranostics is an emerging paradigm that combines imaging and therapy in order to personalize patient treatment. In nuclear medicine, this is achieved by using radiopharmaceuticals that target identical molecular targets for both imaging (using emitted gamma rays) and radiopharmaceutical therapy (using emitted beta, alpha or Auger-electron particles) for the treatment of various diseases, such as cancer. If the therapeutic radiopharmaceutical cannot be imaged quantitatively, a “theranostic pair” imaging surrogate can be used to predict the absorbed radiation doses from the therapeutic radiopharmaceutical. However, theranostic dosimetry assumes that the pharmacokinetics and biodistributions of both radiopharmaceuticals in the pair are identical or very similar, an assumption that still requires further validation for many theranostic pairs. In this review, we consider both same-element and different-element theranostic pairs and attempt to determine if factors exist which may cause inaccurate dose extrapolations in theranostic dosimetry, either intrinsic (e.g. chemical differences) or extrinsic (e.g. injecting different amounts of each radiopharmaceutical) to the radiopharmaceuticals. We discuss the basis behind theranostic dosimetry and present common theranostic pairs and their therapeutic applications in oncology. We investigate general factors that could create alterations in the behavior of the radiopharmaceuticals or the quantitative accuracy of imaging them. Finally, we attempt to determine if there is evidence showing some specific pairs as suitable for theranostic dosimetry. We show that there are a variety of intrinsic and extrinsic factors which can significantly alter the behavior among pairs of radiopharmaceuticals, even if they belong to the same chemical element. More research is needed to determine the impact of these factors on theranostic dosimetry estimates and on patient outcomes, and how to correctly account for them.

show abstract

“…18 F is a radionuclide that has had increased focus for SSTR-targeting peptides [ 37 , 40 ]. It should be noted that other novel radiometals are currently in use and are continuously being investigated due to their similar advantages over 68 Ga, such as 64 Cu, 44 Sc and 89 Zr, with 64 Cu-DOTATOC and 64 Cu-DOTATATE currently being in clinical use as 68 Ga-DOTATOC and 68 Ga-DOTATATE alternatives [ 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 ]. These radiometals also provide attractive alternatives to 68 Ga PET imaging, although they are beyond the scope of this review.…”

Section: Peptidesmentioning

confidence: 99%

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals

et al. 2021

View full text Add to dashboard Cite

The incorporation of silicon fluoride acceptor (SiFA) moieties into a variety of molecules, such as peptides, proteins and biologically relevant small molecules, has improved the generation of 18F-radiopharmaceuticals for medical imaging. The efficient isotopic exchange radiofluorination process, in combination with the enhanced [18F]SiFA in vivo stability, make it a suitable strategy for fluorine-18 incorporation. This review will highlight the clinical applicability of [18F]SiFA-labeled compounds and discuss the significant radiotracers currently in clinical use.

show abstract

64Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors

Cited by 14 publications

References 24 publications

Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets

Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) 18F-Radiopharmaceuticals

Contact Info

Product

Resources

About